Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
117 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Neuropathy - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2016, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape. Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.Diabetic Neuropathy. Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Diabetic Neuropathy Overview 9 Therapeutics Development 10 Pipeline Products for Diabetic Neuropathy - Overview 10 Pipeline Products for Diabetic Neuropathy - Comparative Analysis 11 Diabetic Neuropathy - Therapeutics under Development by Companies 12 Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes 14 Diabetic Neuropathy - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Diabetic Neuropathy - Products under Development by Companies 18 Diabetic Neuropathy - Products under Investigation by Universities/Institutes 20 Diabetic Neuropathy - Companies Involved in Therapeutics Development 21 Achelios Therapeutics, Inc. 21 Araim Pharmaceuticals, Inc. 22 Celgene Corporation 23 Commence Bio, Inc. 24 Glucox Biotech AB 25 KPI Therapeutics, Inc. 26 Lpath, Inc. 27 Medifron DBT Co., Ltd. 28 Neuralstem, Inc. 29 NovaLead Pharma Pvt. Ltd. 30 Novartis AG 31 Omeros Corporation 32 PhiloGene, Inc. 33 Reata Pharmaceuticals, Inc. 34 Relief Therapeutics S.A. 35 Sucampo Pharmaceuticals, Inc. 36 ViroMed Co Ltd 37 Diabetic Neuropathy - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Target 39 Assessment by Mechanism of Action 42 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 49 atexakin alfa - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 benfotiamine - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 BNV-222 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 cibinetide - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 CMB-200 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Cyndacel-M - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 EMA-401 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 ketoprofen - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Lpathomab - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 MDR-652 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 ND-07 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 NLP-198 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 NSI-189 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 NSI-566 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 OMS-721 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 PDA-002 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 pirenzepine hydrochloride - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 RTA-901 - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 RTU-1096 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 Small Molecule for Pain - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 Small Molecules for Diabetic Neuropathy - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 U-2902 - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 VM-202 - Drug Profile 102 Product Description 102 Mechanism Of Action 102 R&D Progress 102 XK-568b - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 Diabetic Neuropathy - Dormant Projects 106 Diabetic Neuropathy - Discontinued Products 110 Diabetic Neuropathy - Product Development Milestones 111 Featured News & Press Releases 111 Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy 111 Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 111 Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 112 Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 114 Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting 114 Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial 115 Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 115 Appendix 116 Methodology 116 Coverage 116 Secondary Research 116 Primary Research 116 Expert Panel Validation 116 Contact Us 116 Disclaimer 117
List of Tables Number of Products under Development for Diabetic Neuropathy, H2 2016 10 Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H2 2016 20 Diabetic Neuropathy - Pipeline by Achelios Therapeutics, Inc., H2 2016 21 Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 22 Diabetic Neuropathy - Pipeline by Celgene Corporation, H2 2016 23 Diabetic Neuropathy - Pipeline by Commence Bio, Inc., H2 2016 24 Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H2 2016 25 Diabetic Neuropathy - Pipeline by KPI Therapeutics, Inc., H2 2016 26 Diabetic Neuropathy - Pipeline by Lpath, Inc., H2 2016 27 Diabetic Neuropathy - Pipeline by Medifron DBT Co., Ltd., H2 2016 28 Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H2 2016 29 Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016 30 Diabetic Neuropathy - Pipeline by Novartis AG, H2 2016 31 Diabetic Neuropathy - Pipeline by Omeros Corporation, H2 2016 32 Diabetic Neuropathy - Pipeline by PhiloGene, Inc., H2 2016 33 Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 34 Diabetic Neuropathy - Pipeline by Relief Therapeutics S.A., H2 2016 35 Diabetic Neuropathy - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 36 Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H2 2016 37 Assessment by Monotherapy Products, H2 2016 38 Number of Products by Stage and Target, H2 2016 40 Number of Products by Stage and Mechanism of Action, H2 2016 43 Number of Products by Stage and Route of Administration, H2 2016 46 Number of Products by Stage and Molecule Type, H2 2016 48 Diabetic Neuropathy - Dormant Projects, H2 2016 106 Diabetic Neuropathy - Dormant Projects (Contd..1), H2 2016 107 Diabetic Neuropathy - Dormant Projects (Contd..2), H2 2016 108 Diabetic Neuropathy - Dormant Projects (Contd..3), H2 2016 109 Diabetic Neuropathy - Discontinued Products, H2 2016 110
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
